SAB Biotherapeutics (NASDAQ: SABS) — Perfil da empresa, notícias e dados financeiros
SAB Biotherapeutics develops human antibodies using its proprietary technology, focusing on advanced treatments for various diseases.
SAB Biotherapeutics
SAB Biotherapeutics (NASDAQ: SABS) pioneers groundbreaking biotechnology solutions with a focus on human antibodies. Their proprietary SAB CAP Technology™ enables the development of fully human polyclonal antibodies without human donors, promising breakthroughs in treating infectious diseases, autoimmune disorders, and cancer. The company's clinical-stage initiatives, such as human anti-thymocyte immunoglobulin (hIgG) for type 1 diabetes, underscore their commitment to advancing healthcare. With a robust immunotherapy platform and a dedication to innovation, SAB Biotherapeutics stands poised to reshape medical treatments and address critical global health challenges, offering hope for improved patient outcomes worldwide.
Resumo
Operações
Produtos e/ou serviços de SAB Biotherapeutics
- Fully Human Polyclonal Antibodies: SAB Biotherapeutics specializes in the development of fully human polyclonal antibodies using their innovative technology platform.
- Immunotherapy Platform: The company offers a cutting-edge immunotherapy platform for the development of novel therapeutic solutions targeting various diseases, including infectious diseases, autoimmune disorders, and cancer.
- Clinical-Stage Therapeutics: SAB Biotherapeutics may have clinical-stage therapeutic candidates targeting specific diseases or medical conditions, such as type 1 diabetes (T1D), utilizing their human anti-thymocyte immunoglobulin (hIgG).
- Research and Development Services: SAB Biotherapeutics might offer research and development services, including collaboration opportunities with pharmaceutical companies, academic institutions, and research organizations.
- Antibody Production Technologies: The company could provide technologies and expertise related to antibody production, purification, and characterization, leveraging their proprietary methods for scalable and cost-effective manufacturing.
- Biotechnology Solutions: SAB Biotherapeutics likely offers a range of biotechnology solutions aimed at advancing medical research, drug discovery, and therapeutic development, with a focus on improving patient outcomes and addressing unmet medical needs.
equipe executiva do SAB Biotherapeutics
- Samuel J. ReichCEO & Director
- Eddie Joe SullivanCo-Founder, President & Director
- Lucy ToExecutive VP & CFO
- Christoph BauschExecutive VP & COO
- Alexandra KropotovaExecutive VP & Chief Medical Officer
- Catherine DeRoseVice President of Human Resources
- Hua WuSenior Vice President of Product Development
- Carlos N. CarilloSenior Vice President of Regulatory Affairs
- Angie ParizekSenior Vice President of Clinical Operations
Principais indicadores financeiros
Resultados divulgados pela SAB Biotherapeutics, em USD.
- Cap. de mercado
- 279,3 mi
- Receita (TTM)
- 114,7 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -49 mi | 13,3 mi | |
| 1,3 mi | -42,9 mi | -34,1 mi | |
| 2,2 mi | -38,1 mi | -42,2 mi | |
| 23,9 mi | -28,9 mi | -18,7 mi |